Table 2.
Serological features of patients with AIH-PBC overlap syndrome and control cohorts.
| Characteristics | AIH-PBC Cohort (n = 90) |
AIH Control Cohort (n = 100) | PBC Control Cohort (n = 100) |
|---|---|---|---|
| ANA, n (%) | 60/84 (71.4) | 83/100 (83) | 23/95 (24.2) |
| Non-specific subtypes of ANA | |||
| Anti-Ro/SSA | 3/17 (17.6) | 4/22 (18.2) | 3/15 (15.8) |
| SSA 52-60 | 4/14 (28.6) | 5/20 (25.0) | 3/16 (18.8) |
| Anti-La/SSB | 0/14 (0) | 4/18 (22.2) | 1/17 (5.9) |
| Anti-Scl 70 | 0/16 (0) | 0/8 (0) | 0/10 (0) |
| ACA | 3/10 (30.0) | 1/21 (4.7) | 2/16 (12.5) |
| Anti-gp210 | 2/15 (13.3) | 0/12 (0) | 3/12 (25.0) |
| Anti-Sp100 | 3/14 (21.4) | 1/12 (8.3) | 4/12 (33.3) |
| Anti-CENP-A | 2/8 (25.0) | 0/13 (0) | 1/17 (5.9) |
| Anti-CENP-B | 4/12 (33.3) | 0/17 (0) | 2/17 (11.8) |
| Anti-dsDNA | 3/27 (11.1) | 6/40 (15.0) | 8/36 (22.2) |
| U1-RNP | 0/9 (0) | 0/8 (0) | 0/10 (0) |
| Sm-RNP | 0/15 (0) | 1/8 (12.5) | 0/6 (0) |
| Anti-PML | 2/14 (14.3) | 0/14 (0) | 7/15 (46.7) |
| ANCA | |||
| pANCA | 4/20 (20.0) | 3/30 (10.0) | 0/32 (0) |
| Anti-MPO | 2/13 (15.4) | 3/29 (10.3) | 0/32 (0) |
| Anti-PR 3 | 2/11 (18.2) | 3/8 (37.5) | 0/15 (0) |
| AMA | 72/90 (80.0) | 6/100 (6.0) | 91/100 (91.0) |
| AMA-M2 | 26/36 (72.2) | 1/16 (6.3) | 8/36 (22.2) |
| AMA-M2-3E | 14/20 (70.0) | 0/8 (0) | 6/14 (42.9) |
| Anti-SMA | 40/60 (66.7) | 24/71 (33.8) | 0/32 (0) |
| Anti-LKM-1 | 2/55 (3.6) | 9/63 (14.3) | 0/32 (0) |
| Anti-LC1 | 1/17 (5.9) | 0/31 (0) | 0/35 (0) |
| Anti-SLA/LP | 5/62 (8.1) | 12/68 (17.6) | 0/38 (0) |
| Anti-Jo1 | 0/17 (0) | 0/12 (0) | 0/29 (0) |
ACA = Anticentromere Antibodies; AMA-M2 = Antimitochondrial Antibodies M2 subtype; AMA M2-3E = Antimitochondrial Antibodies M2-3E subtype; ANA = Antinuclear Antibodies; ANCA = Antineutrophil Cytoplasmic Antibodies; Anti-CENP-A = Antibodies against centromere protein A; Anti-CENP-B = Antibodies against centromere protein B; Anti-dsDNA = Antibodies against double-stranded DNA; Anti-gp210 = Antibodies against glycoprotein 210; Anti-Jo1 = Anti-Histidyl-tRNA Synthetase; Anti-La/SSB = Antibodies against La/SSB antigen; Anti-LC1 = Anti-Liver Cytosol Antibody Type 1; Anti-LKM-1 = Anti-Liver-Kidney-Microsomal Type 1 Antibodies; Anti-MPO = Anti-Myeloperoxidase; Anti-PML = Antibodies against promyelocytic leukemia protein; Anti-PR 3 = Anti-Proteinase 3; Anti-SLA/LP = Anti-Soluble Liver Antigen/ Liver Pancreas; Anti-Ro/SSA = Antibodies against Ro/SSA antigens; Anti-Scl 70 = Antibodies against Scl-70 antigen; Anti-Sp100 = Antibodies against Sp100 protein; pANCA = Perinuclear Antineutrophil Cytoplasmic Antibodies; Sm-RNP = Antibodies against Smith antigen and ribonucleoprotein; SSA 52-60 = Antibodies against RO/SSA 52/60; U1-RNP = Antibodies against U1 ribonucleoprotein.